DelveInsight's "Ataxia Telangiectasia (AT) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Ataxia Telangiectasia (AT) , historical and forecasted epidemiology as well as the Ataxia Telangiectasia (AT) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

1. Ataxia Telangiectasia Market Size,
Epidemiology, Drugs, Leading Companies
and Competitive Landscape
DelveInsight has launched a new report on "Ataxia Telangiectasia (AT) - Market Insights,
Epidemiology, and Market Forecast-2030".
DelveInsight's "Ataxia Telangiectasia (AT) - Market Insights, Epidemiology, and Market Forecast-
2030" report delivers an in-depth understanding of the Ataxia Telangiectasia (AT) , historical and
forecasted epidemiology as well as the Ataxia Telangiectasia (AT) market trends in the United States,
EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the facts:
 As per the National Library of Medicine (2018), Ataxia-Telangiectasia occurs in 1 in 40,000–
100,000 people worldwide.
 According to the National Organization for Rare Disorders (2018), males and females are
affected in equal numbers. In the United States, the prevalence is approximately 1 in
40,000–100,000 live births.
 In the United States, about one percent of the population is a carrier of a mutation in the
Ataxia Telangiectasia mutated kinase (ATM) gene.
 The Orphanet Registry (2018) estimates the average prevalence of Ataxia-Telangiectasia at 1
per 100,000 children. The most reliable estimates for the number of people with Ataxia
Telangiectasia, in the UK at least, are 3 per million.
 As per Jayesh et al., in 2015, the prevalence of patients with Ataxia-Telangiectasia in Europe
was estimated to be 1 per 150,000.
 About 25% of affected individuals have an “atypical” presentation with later onset (age >25
years).
Request for Free Sample Report: https://www.delveinsight.com/sample-request/ataxia-
telangiectasia-at-market
Scope of the Report
 The report covers the descriptive overview of Ataxia Telangiectasia (AT) , explaining its
causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
 Comprehensive insight has been provided into the Ataxia Telangiectasia (AT) epidemiology
and treatment in the 7MM

2.  Additionally, an all-inclusive account of both the current and emerging therapies for Ataxia
Telangiectasia (AT) are provided, along with the assessment of new therapies, which will
have an impact on the current treatment landscape
 A detailed review of Ataxia Telangiectasia (AT) market; historical and forecasted is included
in the report, covering drug outreach in the 7MM
 The report provides an edge while developing business strategies, by understanding trends
shaping and driving the global Ataxia Telangiectasia (AT) market
Request for Free Sample Report: https://www.delveinsight.com/sample-request/ataxia-
telangiectasia-at-market
Ataxia-Telangiectasia (A-T) is a rare inherited disorder that affects the nervous system, immune
system, and other body systems. This disorder is characterized by progressive difficulty in
coordinating movements (ataxia) beginning in early childhood, usually before age 5. Affected
individuals tend to have high amount of a protein called alpha-fetoprotein (AFP) in their blood. It is
categorized as Typical (childhood onset) and Atypical (adult onset).
Mutations in the Ataxia-Telangiectasia mutated kinase (ATM) gene cause ataxia-telangiectasia. The
ATM gene provides instructions for making a protein that helps control cell division and is involved in
DNA repair. This protein plays an important role in the normal development and activity of several
body systems, including the nervous system and immune system. Without this protein, cells become
unstable and eventually die. Cells in the part of the brain involved in coordinating movements (the
cerebellum) are particularly affected by loss of the ATM protein.
Affected children typically develop difficulty in walking, problems with balance and hand
coordination, involuntary jerking movements (chorea), muscle twitches (myoclonus), and
disturbances in nerve function (neuropathy). Its prevalence is same in both male and female.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/ataxia-
telangiectasia-at-market
Some of the Companies Covered:
 Ery Del SpA
 IntraBio
 And Many Others
Drugs Covered:
 EryDex System
 IB1001
 And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/ataxia-
telangiectasia-at-market
Table of Contents:
1. Key Insights
2. Executive Summary of Ataxia Telangiectasia (AT)
3. Competitive Intelligence Analysis for Ataxia Telangiectasia (AT)

3. 4. Ataxia Telangiectasia (AT): Market Overview at a Glance
5. Ataxia Telangiectasia (AT): Disease Background and Overview
6. Patient Journey
7. Ataxia Telangiectasia (AT) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Ataxia Telangiectasia (AT) Treatment
11. Marketed Products
12. Emerging Therapies
13. Ataxia Telangiectasia (AT) : Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Ataxia Telangiectasia (AT)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/ataxia-telangiectasia-
at-market
Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/
LinkedIn | Facebook | Twitter
Get Free Sample Copy of Report at:
https://www.delveinsight.com/sample-request/von-willebrand-disease-pipeline-insight